A recent Ensem Therapeutics Inc. patent details the discovery of tricyclic derivatives acting as GTPase KRAS (mutant) inhibitors for use in the treatment of cancer.
Codeable Therapeutics Inc. has developed new antibody-drug conjugates comprising an antibody covalently linked to a cytotoxic drug for potential use in the treatment of cancer.
CDKs are central regulators of cell-cycle progression in cancer, with resistance to CDK4/6 inhibitors frequently converging on CDK2 activation through cyclin E upregulation or CCNE1 amplification, supporting CDK2 inhibition as a strategy to restore cell-cycle control. Researchers from Novartis AG have revealed the preclinical profile of ECI-830, an oral bioavailable, highly selective ATP-competitive CDK2 inhibitor.
Insilico Medicine Cayman Topco has nominated ISM-0387, an MTA-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor, as a preclinical developmental candidate for glioblastoma. The discovery and optimization process for ISM-0387 was powered by Chemistry42, Insilico’s generative chemistry platform integrated with over 40 generative AI models.
Although CAR T-cell therapy has been highly effective in hematological cancers, its activity in solid tumors is still constrained by inhibitory checkpoints such as PD-1, LAG-3 and TIM-3, together with the lack of locally available cytokines such as IL-2 needed to sustain T-cell function. Anwita Biosciences Inc. and collaborators aimed to overcome these challenges by developing a strategy integrating an immune checkpoint inhibitor (ICI) with a T-cell stimulatory cytokine.
Ribo Life Science Co. Ltd.’s HK$1.8 billion (US$230 million) raise on Jan. 9 was the sole Chinese biotech IPO on the Hong Kong Stock Exchange in the first quarter (Q1) of 2026, despite a growing backlog of more than 70 filings from China life science firms in 2025. Among med-tech companies, Hangzhou Diagens Biotechnology Co. Ltd. debuted with a $101 million Hong Kong IPO March 30, 2026.
Shanghai Meiyue Biotech Development Co. Ltd. has divulged molecular glue degraders comprising an E3 ubiquitin-protein ligase/proto-oncogene Vav (VAV1) interaction inducer and VAV1 degradation inducer. They are designed for potential use in the treatment of cancer, autoimmune diseases, cardiovascular, renal, metabolic, inflammatory and neurological disorders.
Scientists from Jiangsu Hengrui Pharmaceuticals Co. Ltd., Shanghai Senhui Pharmaceutical Co. Ltd. and Shanghai Shengdi Pharmaceutical Co. Ltd. have disclosed antibody-drug conjugates comprising antibodies covalently linked camptothecin derivatives through a linker reported to be useful for the treatment of cancer.
Homozygous deletion of methylthioadenosine phosphorylase (MTAP), present in ~15% of tumors, leads to accumulation of methylthioadenosine and partial inhibition of protein arginine methyltransferase 5 (PRMT5), creating a synthetic-lethal vulnerability that sensitizes tumors to PRMT5-targeted therapies. Researchers from Beone Medicines Ltd. presented preclinical efficacy data of BGB-58067, an MTA-cooperative PRMT5 inhibitor, in models of tumors with MTAP-deficiency.
An advantage of antibody-drug conjugates (ADCs) is that they allow targeted delivery of cytotoxic agents into tumors, thus improving the therapeutic index. Pfizer Inc. has developed a new ADC, PF-08046033, that contains auristatin S (AurS) as the cytotoxic payload and targets transmembrane glycoprotein NMB (GPNMB).
RSS
